MedTrace Logo

Phototoxicity Potential of NatrOVA Creme Rinse - 1%

NCT00591331 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2008-05-20

No results posted yet for this study

Summary

This study will evaluate the primary irritation potential of NatrOVA Creme Rinse - 1% in humans, after exposure to UV radiation.

Conditions

  • Head Lice

Interventions

DRUG

Spinosad (the active ingredient in NatrOVA)

This is a patch test in which the test material is applied to the patch and the patch applied to the skin.

DRUG

placebo

Sponsors & Collaborators

  • ParaPRO LLC

    lead INDUSTRY

Principal Investigators

  • John V Murray, MD · Hill Top Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00591331 on ClinicalTrials.gov